As part of the BRECISE IHI Consortium, Swiss startup Novigenix has been awarded EUR 1.8M funded by the European Union (EU) research initiative focusing on revolutionizing cancer diagnostics, treatment, and monitoring through advanced multi-omics and artificial intelligence. A leader in AI-driven precision liquid biopsy solutions, Novigenix’s will be vital for the prediction of immunotherapy response.
The BRECISE consortium was launched in Madrid during the 40th meeting of the European Association of Urology Congress. The multi-stakeholder collaborative effort, co-funded by the Innovative Health Initiative (IHI) under the Horizon Europe program, aims to transform patient care by integrating Next-Generation Sequencing (NGS)-based biomarkers with AI-driven decision-making frameworks. BRECISE seeks to address critical challenges in oncology, particularly in prostate and bladder cancer, by accelerating the clinical validation of multi-modal biomarkers.
Current oncology programs struggle with accurate prediction of patient response, often leading to suboptimal treatment and poor patient outcomes. By integrating whole blood RNA sequencing with circulating tumor DNA (ctDNA) analysis, Novigenix’s LITOSeek platform provides unprecedented level prediction of clinical benefit providing next generation liquid biopsy for:
- Better patient stratification: identifying responders and non-responders to specific therapies with increased precision.
- Improved adverse event prediction: reducing treatment-related complications by enhancing risk assessment.
- Optimized drug development: supporting biopharma partners in selecting the right patient populations for clinical trials, improving efficiency and success rates.
Brian Hashemi, CEO of Biopôle-besed Novigenix, said: “Our participation in BRECISE marks another major milestone in our mission to improve patient outcomes through data-driven precision oncology. Our contribution is to bring the expertise we have built over a decade of developing AI-powered liquid biopsy solutions, including LITOSeek, which provides unparalleled predictive insights into immune response to tumor biology, and therapy resistance through the integration of transcriptomic and genomic biomarkers with advanced AI modelling.”
Dr. Ralf Hoffmann, Principal at Philips Research and industry project leader for BRECISE, said: “BRECISE represents a paradigm shift in precision oncology and cancer care. By using advanced NGS technologies and AI integration to validate biomarker models, we can enable personalized treatment for prostate and bladder cancer patients. This approach not only improves patient outcomes but also optimizes healthcare resources by guiding more accurate and efficient treatment decisions. BRECISE is bringing the future of cancer care into the present”.
(Press release)
